BACKGROUND: COBRA™ (COnditional Bispecific Redirected Activation) T-cell engagers are designed to target solid tumors as a single polypeptide chain prodrug that becomes activated by proteolysis in the tumor microenvironment. One COBRA molecule comprises seven Ig domains: three single-domain antibodies (sdAbs) recognizing a tumor target or human serum albumin (HSA), and CD3ε-binding variable fragment heavy chain (VH) and variable fragment light chain (VL) and their inactivated counterparts, VHi and VLi. Pairing of VH and VL, and VLi and VHi into single-chain variable fragments (Fv) is prevented by shortened inter-domain linkers. Instead, VH and VL are expected to interact with VLi and VHi, respectively, thus making a diabody whose binding to CD3ε on the T-cells is impaired. METHODS: We analyzed the structure of an epidermal growth factor receptor (EGFR) COBRA in solution using negative stain electron microscopy (EM) and small-angle X-ray scattering (SAXS). RESULTS: We found that this EGFR COBRA forms stable monomers with a very dynamic interdomain arrangement. At most, only five domains at a time appeared ordered, and only one VH-VL pair was found in the Fv orientation. Nonenzymatic posttranslational modifications suggest that the CDR3 loops in the VL-VHi pair are exposed but are buried in the VH-VLi pair. The MMP9 cleavage rate of the prodrug when bound to recombinant EGFR or HSA is not affected, indicating positioning of the MMP9-cleavable linker away from the EGFR and HSA binding sites. CONCLUSION: Here, we propose a model for EGFR COBRA where VH and VLi form an Fv, and VL and VHi do not, possibly interacting with other Ig domains. SAXS and MMP9 cleavage analyses suggest that all COBRA molecules tested have a similar structural architecture.
BACKGROUND: COBRA™ (COnditional Bispecific Redirected Activation) T-cell engagers are designed to target solid tumors as a single polypeptide chain prodrug that becomes activated by proteolysis in the tumor microenvironment. One COBRA molecule comprises seven Ig domains: three single-domain antibodies (sdAbs) recognizing a tumor target or human serum albumin (HSA), and CD3ε-binding variable fragment heavy chain (VH) and variable fragment light chain (VL) and their inactivated counterparts, VHi and VLi. Pairing of VH and VL, and VLi and VHi into single-chain variable fragments (Fv) is prevented by shortened inter-domain linkers. Instead, VH and VL are expected to interact with VLi and VHi, respectively, thus making a diabody whose binding to CD3ε on the T-cells is impaired. METHODS: We analyzed the structure of an epidermal growth factor receptor (EGFR) COBRA in solution using negative stain electron microscopy (EM) and small-angle X-ray scattering (SAXS). RESULTS: We found that this EGFR COBRA forms stable monomers with a very dynamic interdomain arrangement. At most, only five domains at a time appeared ordered, and only one VH-VL pair was found in the Fv orientation. Nonenzymatic posttranslational modifications suggest that the CDR3 loops in the VL-VHi pair are exposed but are buried in the VH-VLi pair. The MMP9 cleavage rate of the prodrug when bound to recombinant EGFR or HSA is not affected, indicating positioning of the MMP9-cleavable linker away from the EGFR and HSA binding sites. CONCLUSION: Here, we propose a model for EGFR COBRA where VH and VLi form an Fv, and VL and VHi do not, possibly interacting with other Ig domains. SAXS and MMP9 cleavage analyses suggest that all COBRA molecules tested have a similar structural architecture.
Authors: Kevin N Dyer; Michal Hammel; Robert P Rambo; Susan E Tsutakawa; Ivan Rodic; Scott Classen; John A Tainer; Greg L Hura Journal: Methods Mol Biol Date: 2014
Authors: Even Walseng; Christopher G Nelson; Junpeng Qi; Alex R Nanna; William R Roush; Rajib K Goswami; Subhash C Sinha; Terrence R Burke; Christoph Rader Journal: J Biol Chem Date: 2016-07-21 Impact factor: 5.157
Authors: Eva Maria Herold; Christine John; Benedikt Weber; Stephan Kremser; Jonathan Eras; Carolin Berner; Sabrina Deubler; Martin Zacharias; Johannes Buchner Journal: Sci Rep Date: 2017-09-25 Impact factor: 4.379
Authors: Adam R Root; Wei Cao; Bilian Li; Peter LaPan; Caryl Meade; Jocelyn Sanford; Macy Jin; Cliona O'Sullivan; Emma Cummins; Matthew Lambert; Alfredo D Sheehan; Weijun Ma; Scott Gatto; Kelvin Kerns; Khetemenee Lam; Aaron M D'Antona; Lily Zhu; William A Brady; Susan Benard; Amy King; Tao He; Lisa Racie; Maya Arai; Dianah Barrett; Wayne Stochaj; Edward R LaVallie; James R Apgar; Kristine Svenson; Lidia Mosyak; Yinhua Yang; Gurunadh R Chichili; Liqin Liu; Hua Li; Steve Burke; Syd Johnson; Ralph Alderson; William J J Finlay; Laura Lin; Stéphane Olland; William Somers; Ezio Bonvini; Hans-Peter Gerber; Chad May; Paul A Moore; Lioudmila Tchistiakova; Laird Bloom Journal: Antibodies (Basel) Date: 2016-03-04
Authors: Anand Panchal; Pui Seto; Russell Wall; Brian J Hillier; Ying Zhu; Jessica Krakow; Aakash Datt; Elizabeth Pongo; Andisheh Bagheri; Tseng-Hui T Chen; Jeremiah D Degenhardt; Patricia A Culp; Danielle E Dettling; Maia V Vinogradova; Chad May; Robert B DuBridge Journal: MAbs Date: 2020 Jan-Dec Impact factor: 5.857